Bladder Cancer Clinical Trial
Official title:
A Phase II Clinical Trial of Neoadjuvant Chemotherapy With M-VAC Plus Avastin in Patients With Locally Advanced Urothelial Cancer
The goal of this clinical research study is to learn how well bladder cancer responds to a
combination treatment with Avastin and M-VAC (methotrexate, doxorubicin, vinblastine, and
cisplatin) before surgery to remove the tumor.
Primary Objective:
To estimate the response of patients with locally advanced urothelial cancer treated with
neoadjuvant chemotherapy with a combination of Dose Dense Methotrexate, Vinblastine,
Adriamycin, and Cisplatin (DD-M-VAC) plus Avastin followed by radical surgery with curative
intent. In this context, response will be defined as the absence of residual muscle invasive
cancer in the resected specimen (<= pT1, N0.)
Secondary Objective:
To estimate the 4-year disease-free survival of patients with locally advanced urothelial
cancer treated with neoadjuvant chemotherapy with DD-M-VAC plus Avastin followed by radical
surgery with curative intent.
Document perioperative morbidity and mortality in this cohort, with reference to
well-established historical standards.
Determine the effects of VEGF inhibition on angiogenesis and angiogenesis-related gene
expression utilizing fluorescent tissue staining techniques that we have developed in the
laboratory (such as two-color TUNEL, phospho-receptor, and microvessel density).
Interrogate downstream receptor signaling pathways to provide insight into the development
of chemotherapy resistance, and hence hypothesis for its prevention.
Avastin is designed to prevent or slow down the growth of cancer cells by blocking the
growth of blood vessels. Methotrexate, vinblastine, and doxorubicin are designed to disrupt
the growth of cancer cells, which causes cancer cells to start to die. Cisplatin has an atom
at its center that contains platinum. The platinum is designed to poison the cancer cells,
which may cause them to eventually die.
If you are found to be eligible to take part in this study, you will be treated with the
combination of Avastin, methotrexate, vinblastine, doxorubicin, and cisplatin. The study
drugs and saline will be given through a needle in your vein. Avastin will be given over 90
minutes. Methotrexate will be given over 30 minutes. Vinblastine will be given over 30
minutes. Doxorubicin will be given over 15 minutes. Cisplatin will be given over 4 hours.
You will also receive saline for hydration after you have completed the infusion of
cisplatin. This will take up to 20 hours. If you have a catheter in place, the chemotherapy
drugs as well as the saline will be given through the catheter. You will receive the study
drugs 1 time every 2 weeks. Every 2 weeks is called a study "cycle".
On Day 1 of each cycle, you will have a physical exam, including measurement of your vital
signs, height, and weight. You will be asked about any side effects you have experienced
since your last visit. Blood (about 2 teaspoons) and urine will be collected for routine
tests.
After 3 cycles of therapy, you will have a bone scan if your screening test showed signs of
bone disease. You will also have a repeat cystoscopy. These tests will be done to check the
status of the disease.
You will receive a total of 4 cycles of chemotherapy. At least 6 weeks after the last dose
of Avastin, you will have a cystectomy (removal of your tumor). Your doctor will explain
this procedure to you in detail. You will sign a separate consent form for this procedure.
After surgery, if you do not have disease in your lymph nodes or other sites, you will be
taken off-study.
After surgery, if you still have disease in your lymph nodes or other sites, you will be
eligible to continue treatment with Avastin. Therapy can be restarted no sooner than 28 days
after your surgery. You will receive Avastin every 2 or 3 weeks through a needle in your
vein. Every 2 or 3 weeks will be considered a study cycle.
Before each cycle of treatment, blood (about 1 teaspoon) will be drawn for routine tests.
Urine will be collected every cycle for routine testing. Every 3 months you will have a CT
scan or MRI to check the status of the disease.
You may continue to receive the study drug for up to 18 months of therapy. You will be taken
off study in the disease gets worse or intolerable side effects occur.
Once you are off-study, you will have long term follow-up visits every 3-6 months for the
first 30 months and then every year after that. These visits will continue for up to 4
years, or longer if your doctor thinks it is necessary. At these visits, you will have a CT
or MRI scan of your abdomen and pelvis and a chest x-ray. Blood (about 1 teaspoons) will be
drawn for routine testing.
This is an investigational study. Avastin is not FDA approved or commercially available for
this indication. Its use in this study is considered to be investigational. Methotrexate,
doxorubicin, vinblastine, and cisplatin are all FDA approved and commercially available. Up
to 60 patients will take part in this study. All will be enrolled at MD Anderson.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |